



### Agenda

**Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)  
18 - 20 October 2016  
Centre International de Conférences Genève (CICG), Geneva**

#### **Tuesday, 18 October 2016**

<b>Time</b>	<b>Session</b>	<b>Purpose of session, target outcomes and questions for SAGE</b>	<b>Duration</b>
8:30	<b>Welcome – introduction of participants</b>  J. Abramson, Chair of SAGE.		20 min.
8:50	<b>Report from Director, IVB - Session 1</b>  Global report including key updates and challenges from regions. J.-M. Okwo-Bele, WHO. 40 min.  Discussion: 1h 20 min.	<b>FOR INFORMATION</b>	2h
<b>09:50</b>	<b>Coffee/Tea break</b>	<b>Break</b>	<b>30 min.</b>
10:20	<b>Report from Director, IVB – Session 1, contd.</b>  Discussion contd.		
11:20	<b>Report from Gavi, the Vaccine Alliance - Session 2</b>  Report from Gavi, the Vaccine Alliance. A. Nguyen, Gavi, the Vaccine Alliance. 20 min.  Discussion: 20 min.	<b>FOR INFORMATION</b>	40 min.
12:00	<b>Lunch</b>	<b>Break</b>	<b>1h 30 min.</b>

13:30	<p><b>Reports from other Advisory Committees on Immunization – Session 3</b></p> <p>Report of the Global Advisory Committee on Vaccine Safety (GACVS). R. Pless, Chair of GACVS. 10 min.</p> <p>Discussion: 10 min.</p> <p>Product Development for Vaccines Advisory Committee (PDVAC) D. Kaslow, Chair of PDVAC. 10 min.</p> <p>Discussion: 10 min.</p> <p>Report of the Immunization and vaccines related implementation research advisory committee (IVIR-AC), R. Breiman, Chair of IVIR-AC. 10 min.</p> <p>Discussion: 10 min.</p>	<b>FOR INFORMATION</b>	1h
14:30	<p><b>Report of activities from international immunization partners - Session 4</b></p> <p>Bill and Melinda Gates Foundation (BMGF), O. Levin, BMGF. 20 min.</p> <p>Discussion: 20 min.</p> <p>World Bank, T. Palu, World Bank 20 min.</p> <p>Discussion: 20 min.</p>	<b>FOR INFORMATION</b>  Continuation of the series of presentations initiated in October 2015 to be held at SAGE meetings on the immunization-related activities of partners working in the field of immunization.	1h 20 min.
<b>15:50</b>	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
16:20	<p><b>Polio eradication initiative - Session 5</b></p> <p>Objective of the session and overview of Global Polio Eradication Initiative, M. Zaffran, WHO. 20 min.</p> <ul style="list-style-type: none"> <li>▪ WPV and cVDPV2 elimination</li> <li>▪ Other objectives in the GPEI Strategy Plan (2013-18)</li> </ul> <p>Updates on implementation of OPV2 withdrawal, D. Chang-Blanc, WHO. 20 min</p> <p>Discussion: 20 min</p>	<b>FOR INFORMATION AND DISCUSSION</b>  This session will include an update on the switch and the progress with polio eradication and an initial discussion on post eradication.  To inform and update SAGE on the: <ul style="list-style-type: none"> <li>• Current status of the polio eradication program</li> </ul>	2h 30 min.

	<p>Report from SAGE Polio WG, Y. AL-Mazrou, Chair of the Polio WG. 20 min.</p> <ul style="list-style-type: none"> <li>▪ Summary of WG meeting</li> <li>▪ Future immunization policy: Updates</li> </ul> <p>Discussion: 1h 10 min.</p>	<ul style="list-style-type: none"> <li>• Update on implementation of OPV2 withdrawal and remaining issues</li> <li>• Discussions on future immunization policy after OPV withdrawal and update on the implementation of biocontainment of polioviruses</li> </ul> <p>To ask for SAGE's guidance on:</p> <ul style="list-style-type: none"> <li>• Options for post-OPV immunization policy for further considerations</li> </ul>	
<b>18:50</b>	<b>End of Day</b>		
<b>19:00</b>	<b>Cocktail</b>		

**Wednesday, 19 October 2016**

8:00	<p><b>Measles and rubella elimination - Session 6</b></p> <p>Global measles and rubella update, P. Strebel, WHO. 20 min.</p> <p>Findings and recommendations of the Mid Term Review of the measles and rubella strategic plan 2012-2020, W. Orenstein, Emory University. 30 min.</p> <p>Discussion: 60 min.</p> <p>Measles second dose introduction criteria, N. Turner, SAGE member, 15 min.</p> <p>Discussion: 25 min.</p>	<p><b>FOR DISCUSSION AND DECISION</b></p> <p><b>FOR DISCUSSION</b></p> <ul style="list-style-type: none"> <li>To review the current status of global measles and rubella control and regional elimination.</li> </ul> <p><b>FOR DECISION</b></p> <ul style="list-style-type: none"> <li>SAGE is requested to review the Mid Term Review findings and recommendations and endorse the recommendations.</li> <li>SAGE is requested to decide on whether or not to remove the introduction criteria for MCV2.</li> </ul>	<b>2h 30min.</b>
<b>10:30</b>	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
11:00	<p><b>Maternal and neonatal tetanus elimination and overall tetanus prevention - Session 7</b></p> <p>Introduction, K. Johansen, Chair of Working group on maternal and neonatal tetanus elimination and overall tetanus prevention, 5 min.</p> <p>Update on the current MNTE strategy, achievements, successes and challenges including country experiences, A. Raza, UNICEF, 15 min.</p> <p>Discussion: 10 min.</p> <p>Broader tetanus prevention: Impact of current tetanus immunization programmes and need for acquiring broader tetanus prevention, R. Steinglass, Members of the Working group on maternal and neonatal tetanus elimination and overall tetanus prevention, 15 min.</p> <p>Discussion: 10 min.</p>	<p><b>FOR DECISION</b></p> <p>Based on its working group input, SAGE will be expected to provide recommendations on:</p> <ol style="list-style-type: none"> <li>resetting the agenda, with interim milestones, for achieving MNTE;</li> <li>steps that could be taken to increase visibility and political advocacy of MNTE;</li> <li>how to overcome known and anticipated bottlenecks to achieving MNTE, including recommendations on how achieving the above outcomes will require different approaches by setting or typology;</li> <li>strategies for sustaining MNTE elimination in countries that have achieved MNTE with targeted immunization strategies, including recommendations on methods for documenting sustained elimination;</li> </ol>	<b>2h 30 min</b>

	<p>Review of key conclusions and recommendations by the working group, K. Johansen, Chair of Working group on maternal and neonatal tetanus elimination and overall tetanus prevention, 35 min.</p> <p>Discussion: 1h</p>	<p>5. strategies to achieve broader tetanus prevention (i.e. including all age groups and both genders; 6. any necessary adjustments to the policy recommendations in the WHO tetanus position paper.</p>	
<b>13:30</b>	<b>Lunch</b>	<b>Break</b>	<b>1h</b>
14:30	<p><b>Global Vaccine Action Plan (GVAP): Progress report - Session 8</b></p> <p>The GVAP Secretariat Report 2016: Update on process, new indicators, actions taken by the secretariat in response to previous reports, T. Cherian (on behalf of the Secretariat of the Decade of Vaccines Working Group), WHO. 15 min.</p> <p>Discussion: 15 min.</p> <p>Summary of GVAP implementation progress review and recommendations for corrective actions at the mid-term of the Decade of Vaccines, A. Cravioto, Member of the SAGE Decade of Vaccines Working Group. 30 min.</p> <p>Discussion: 2h</p>	<p><b>FOR DISCUSSION AND DECISION</b></p> <p>SAGE will be expected to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan.</p> <p>Specially, SAGE will be asked to:</p> <ul style="list-style-type: none"> <li>Review the DoV WG "Assessment report on DoV progress 2016" based on the "GVAP Secretariat report 2016", regional reports on the implementation of regional vaccine action plans, priority country reports and some Independent stakeholder submissions.</li> <li>Make recommendations on any necessary changes to the formulation of the indicators, operational definitions and/or the processes for data collection.</li> <li>Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed.</li> </ul> <p>Provide recommendations and corrective actions for Members States, regions, partners, donor agencies "SAGE Assessment report on the Decade of Vaccines progress" which will be the basis of the "progress report" for the WHO Executive Board and World Health Assembly.</p>	
<b>16:00</b>	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
16:30	<b>Global Vaccine Action Plan (GVAP): Progress report - Session 8, Contd.</b>		
<b>18:00</b>	<b>End of day</b>		

**Thursday, 20 October 2016**

08:00	<p><b>Hepatitis B vaccination- Session 9</b></p> <p>Introduction and key questions for the session. K. Johansen, SAGE member. 5 min.</p> <p>Hepatitis B infection -related disease burden, Immunogenicity and safety of hepatitis B vaccine schedules and thermostability of hepatitis B vaccines. F. de la Hoz Restrepo, Colombia National University. 25 min.</p> <p>Observed and forecasted impact of different hepatitis B immunization schedules and strategies. J. Edmunds, London School of Hygiene and Tropical Medicine. 20 min.</p> <p>Conclusions and proposed recommendations for SAGE. K. Johansen, SAGE member. 10 min.</p> <p>Discussion: 1 hr.</p>	<p><b>FOR DECISION</b></p> <p>Present SAGE with updated evidence on hepatitis B infection-related burden, immunogenicity and safety of hepatitis B containing vaccines, the impact of hepatitis B containing vaccines immunization programmes and the thermostability of the monovalent formulation. Focus is on evidence relevant to low- and middle-income countries.</p> <p>Request SAGE's consideration of the following questions:</p> <ul style="list-style-type: none"> <li>• Do the current schedule recommendations require any modifications?</li> <li>• What is the impact of the vaccination programme on the epidemiology of hepatitis B when providing a timely vaccine birth dose?</li> <li>• Does the available evidence support flexibility in the requirement for cold chain storage of hepatitis B vaccines in order to expand the delivery of the birth dose?</li> </ul> <p>SAGE recommendations may be used to update the 2009 WHO position paper on the use of hepatitis B vaccines.</p>	2h
<b>10:00</b>	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
10:30	<p><b>HPV vaccines - Session 10</b></p> <p>Introduction and key questions for the session. A. Pollard, SAGE Member. 5 min.</p> <p>Update on HPV vaccine introduction and programmatic perspective. I. Ogbuanu, WHO. 15 min.</p>	<p><b>FOR DECISION</b></p> <p>Present SAGE with updated evidence on HPV-related burden, HPV vaccines, impact of HPV immunization programmes, and modelling of impact of HPV immunization schedules and strategies. Focus is on evidence relevant to low- and middle-income countries.</p> <p>Request SAGE's consideration of the following questions:</p>	<b>2h15min</b>

	<p>HPV-related disease burden and effects of different HPV immunization schedules and strategies. M. Ramsay, Public Health England. 20 min.</p> <p>Observed and forecast impact of different HPV immunization schedules and strategies. M. Brisson, Laval University. 20 min.</p> <p>Conclusions and proposed recommendations for SAGE. A. Pollard, SAGE Member. 15 min.</p> <p>Discussion: 1 h</p>	<ul style="list-style-type: none"> <li>• What is the incremental effectiveness and cost-effectiveness for cervical cancer prevention of different HPV vaccines based on girls-only immunization?</li> <li>• What is the incremental effectiveness and cost-effectiveness for prevention of HPV-related diseases of adolescent gender-neutral HPV immunization compared to girls-only HPV immunization?</li> <li>• What is the incremental effectiveness and cost-effectiveness for cervical cancer prevention of multiple age cohort HPV immunization of females (within a defined age range) compared to single age cohort immunization of girls-only or of both girls and boys aged 9–13 years?</li> </ul> <p>SAGE recommendations may be used to update WHO position paper on HPV vaccines, which was published in October 2014.</p>	
<b>12:45</b>	<b>Lunch</b>	<b>Break</b>	<b>1h</b>
13:45	<p><b>Yellow Fever - Session 11</b></p> <p>Introduction. C. Siegrist, SAGE member. 5 min.</p> <p><i>Part 1: Long term Yellow Fever strategy</i></p> <p>Epidemiology and risk of yellow fever in current context. O. Tomori, Redeemers University, 15 min.</p> <p>Yellow fever vaccine supply: Projected availability and opportunities for scaling up. A. Costa, WHO, 10 min.</p> <p>Global Strategy for Eliminating Yellow fever Epidemics (EYE). O. Ronveaux, WHO, 15 min.</p> <p>Discussion: 1 hr.</p> <p><i>Part 2: Options for emergency surge capacity</i></p>	<p><b>FOR DISCUSSION AND DECISION</b></p> <p>SAGE is asked to provide feedback on the general approach of the “Global Strategy for Eliminating Yellow fever Epidemics (EYE)”.</p> <p>SAGE is asked to provide recommendations and research priorities for fractional dose use of Yellow fever vaccine as a response to major outbreaks.</p>	<b>3h</b>

	<p>Introduction and context to surge capacity needs. J. Hombach, WHO, 5 min.</p> <p>Fractional dosing of Yellow fever vaccines: review of vaccine potency &amp; stability information, available evidence, and evidence gaps. A. Barrett, University of Texas Medical Branch. 15 min.</p> <p>Feedback from the DRC Yellow fever fractional dose campaign, R. Mihigo, WHO-AFRO, 10 min.</p> <p>Secretariat recommendations and key research needs. J. Hombach, WHO. 5 min.</p> <p>Discussion 40 min.</p>		
<b>16:45</b>	<b>Closing</b>		20 min.
<b>17:00</b>	<b>End of meeting</b>		